
|Articles|December 11, 2006
Are transdermal patches the way of the future?
This past April, methylphenidate (Daytrana, Shire) was approved as a transdermal drug delivery system (TD-DDS) for the treatment of attention deficit hyperactivity disorder. And many more patches are on the horizon. Novartis is seeking Food & Drug Administration approval for its rivastigmine (Exelon) patch to aid in the treatment of Alzheimer's disease. Researchers in the United Kingdom are working on a TD-DDS to deliver synthetic cannabinoids for use as antiemetics and appetite stimulants in patients with AIDS and cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
2
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
3
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5






































